Oncolytic Immunotherapy: Where Are We Clinically? by Akseli Hemminki

Get full text

Survival, Incidence, and Mortality Trends in Female Cancers in the Nordic Countries by Filip Tichanek, Asta Försti, Otto Hemminki, Akseli Hemminki, Kari Hemminki

Get full text

Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial by Tuomo Alanko, Akseli Hemminki, Víctor Cervera-Carrascón, Riikka Havunen, Kristian Taipale, Dafne C A Quixabeira, Jorma Sormunen, Katriina Peltola, Suvi Sorsa, Santeri A Pakola, Elise Jirovec, Lyna Haybout, Claudia Kistler, Tatiana V Kudling, Victor Arias, James H A Clubb, Mirte van der Heijden, Teijo Pellinen, Joao M Santos

Get full text

The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial by Matthew Stephen Block, James Hugo Armstrong Clubb, Johanna Mäenpää, Santeri Pakola, Dafne Carolina Alves Quixabeira, Tatiana Kudling, Elise Jirovec, Lyna Haybout, Mirte van der Heijden, Sanae Zahraoui, Susanna Grönberg-Vähä-Koskela, Sini Raatikainen, Victor Arias, Saru Basnet, Nea Ojala, Teijo Pellinen, Annabrita Hemmes, Katja Välimäki, Annukka Pasanen, Tuomo Alanko, Daniel Adamo, Susan Ramadan, Jorma Sormunen, Juha Kononen, Julia Wanda Cohen, Michael Jon Chisamore, John Goldfinch, Suvi Sorsa, Riikka Havunen, Claudia Kistler, Aino Kalervo, Víctor Cervera-Carrascon, João Manuel dos Santos, Akseli Hemminki

Get full text